Sue Sutton, VP Business Development at OGT, said: “OGT continues to develop its licensing programme and is pleased to license our sequence variation patents to Biotype. These patents are an important part of OGT’s broad patent portfolio and, together with Biotype’s microarray platform, gives customers access to a new, comprehensive way of detecting commercially important wood-rotting fungi.”
Wilhelm Zorgiebel, Executive Director at Biotype, commented: "We are pleased to enter into this licensing arrangement with OGT, a company that is recognised as being at the forefront of molecular technology. This agreement helps us to develop our own microarray technology platform for various applications in medicine and analytics. Our first product, which is completely unique in the market, is the Mycotype® BasidioQS Microarray Detection Kit, which allows the fast and sensitive, simultaneous analysis of the 27 most important wood-rotting basidiomycetes in Europe.”
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk W: www.ogt.co.uk
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomic in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
About Biotype
Biotype Diagnostic GmbH was founded in 1999. It is situated in the GebäudeEnsemble Deutsche Werkstätten Hellerau in the north of Dresden, Germany. The company specialises in genotyping and in molecular biological analysis employed in forensics, human or veterinary medicine, as well as in construction surveys. Biotype develops, produces and distributes molecular genetic test systems for fast and sensitive PCR diagnostics. The product portfolio varies from test kits for genetic identification of humans and animals, in vitro diagnostics in human medicine, as well as for molecular detection of human and veterinary pathogens, to a complete-kit for diagnostics of wood-rotting fungi applied in construction surveys. All products are based on the technology of multiplex PCR for subsequent analysis using microarray detection, capillary gel electrophoresis or Real-Time-PCR. For further information on Biotype visit http://www.biotype.de
